The TGF-β1/miR-106b/DAB2 axis could provide further insight into the pathogenesis of cervical carcinoma, and miR-106b could be a biomarker and potential therapeutic target in cervical cancer. The gene discussed is DAB2; the disease is cervical carcinoma.